The nice people at “The Oncologist” sent their update today. Sometimes they give a web
link; sometimes they don’t. Today they didn’t, which is a pain as it makes
providing evidence of what I’ve done that bit trickier.
Today’s missive contained all sorts of stuff
including:
Michael J. Birrer, Ilaria Betella, Lainie P. Martin, Kathleen N. Moore
Prognosis for women with epithelial
ovarian cancer remains poor. One new molecular target in epithelial ovarian
cancer is folate receptor alpha (FRα). This commentary discusses the characteristics
that contribute to its attractiveness as a candidate for therapeutic
intervention.
Emmanuel S. Antonarakis
Immune checkpoint agents have not yet been approved for use in advanced
prostate cancer. This commentary summarizes the challenges related to this
issue, in light of a recently reported case of a patient with DNA
mismatch-repair deficient castration-resistant prostate cancer who responded to
single-agent pembrolizumab treatment.
Jennifer G. Le-Rademacher, Aminah
Jatoi
No comments:
Post a Comment